Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- PolarityTE
- Target Recruit Count
- 100
- Registration Number
- NCT06140303
- Locations
- 🇺🇸
Titan Clinical Research, Mesa, Arizona, United States
🇺🇸Center for Clinical Research, San Francisco, California, United States
🇺🇸Limb Preservation Platform, Inc., Fresno, California, United States
Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs
- Conditions
- Diabetic Foot
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- PolarityTE
- Target Recruit Count
- 42
- Registration Number
- NCT05372809
- Locations
- 🇺🇸
Limb Preservation Platform, INC, Fresno, California, United States
🇺🇸LA Foot and Ankle Clinic, Los Angeles, California, United States
🇺🇸Royal Research, Corp, Hollywood, Florida, United States
SkinTE™ in the Treatment of Diabetic Foot Wounds
- Conditions
- Diabetic Foot UlcerDiabetic FootUlcer Foot
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- PolarityTE
- Target Recruit Count
- 100
- Registration Number
- NCT03881254
- Locations
- 🇺🇸
Martinsville Research Institute, Martinsville, Virginia, United States
SkinTE® in the Treatment of Venous Leg Wounds
- Conditions
- Venous Leg UlcerVenous StasisVenous Stasis Ulcer
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- PolarityTE
- Target Recruit Count
- 29
- Registration Number
- NCT03881267
- Locations
- 🇺🇸
Martinsville Research Institute, Martinsville, Virginia, United States
🇺🇸Professional Education and Research Institute, Roanoke, Virginia, United States
News
Cell and Gene Therapies Show Promise in Treating Diabetes and Related Complications
ProKidney focuses on its US-based Phase 3 trial of rilparencel for type 2 diabetes and chronic kidney disease, discontinuing a trial in Spain.